December 15th, 2015

Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen’s TECFIDERA approved in the European Union

[theflyonthewall.com] – Biogen announced that TECFIDERA has been approved by the European Commission as a first-line oral treatment for people with relapsing-remitting multiple sclerosis. Biogen will begin to introduce TECFIDERA . . . → Read More: Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen’s TECFIDERA approved in the European Union Similar Articles: Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – UPDATE 2-Biogen profit rises as new multiple sclerosis drug shines Company Update – Gilead Sciences Inc. (NASDAQ:GILD) – European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Biogen wins protection for MS drug Tecfidera in Europe
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.